NCT03901989

Brief Summary

This study investigates the effect of zeolite on bone mineral metabolism. The clinical parameters include bone mineral density, bone remodelling markers, fractures and fallings, the subjective evaluation of the overall health status and intensity of the musculoskeletal pain measured by VAS.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2015

Typical duration for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 14, 2015

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 20, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 20, 2017

Completed
2 years until next milestone

First Submitted

Initial submission to the registry

March 8, 2019

Completed
26 days until next milestone

First Posted

Study publicly available on registry

April 3, 2019

Completed
Last Updated

April 3, 2019

Status Verified

April 1, 2019

Enrollment Period

2.2 years

First QC Date

March 8, 2019

Last Update Submit

April 2, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change of BMD (Bone mineral density)

    BMD measurements are used to see how well osteoporosis treatments are working

    0-6-12 months

Secondary Outcomes (2)

  • Cange of Bone remodelling marker Osteocalcin

    0-6-12 months

  • Cange of Bone remodelling marker Betacross laps

    0-6-12 months

Other Outcomes (3)

  • Fractures and fallings

    12 months

  • Intensity of the musculoskeletal pain measured by VAS

    0-12 months

  • Subjective evaluation of the overall health status and 6.

    0-12 months

Study Arms (2)

zeolite

ACTIVE COMPARATOR

50 subjects receive the substance 3 times per day as powder

Device: zeolite

cellulose

PLACEBO COMPARATOR

50 subjects receive the substance 3 times per day as powder

Device: cellulose

Interventions

zeoliteDEVICE

given for a period of 12 months

zeolite
celluloseDEVICE

given for a period of 12 months

cellulose

Eligibility Criteria

Age40 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • subjects with osteoporosis Among those, as a subgroup, 20 subjects with diabetes type 2 and osteoporosis
  • The osteoporosis- was diagnosed by standard DXA measurement (BMD T-score: - 2.5 or below )

You may not qualify if:

  • chronic renal failure, secondary osteoporosis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Kraljevic Pavelic S, Saftic Martinovic L, Simovic Medica J, Zuvic M, Perdija Z, Krpan D, Eisenwagen S, Orct T, Pavelic K. Clinical Evaluation of a Defined Zeolite-Clinoptilolite Supplementation Effect on the Selected Blood Parameters of Patients. Front Med (Lausanne). 2022 May 27;9:851782. doi: 10.3389/fmed.2022.851782. eCollection 2022.

  • Kraljevic Pavelic S, Micek V, Bobinac D, Bazdulj E, Gianoncelli A, Krpan D, Zuvic M, Eisenwagen S, Stambrook PJ, Pavelic K. Treatment of osteoporosis with a modified zeolite shows beneficial effects in an osteoporotic rat model and a human clinical trial. Exp Biol Med (Maywood). 2021 Mar;246(5):529-537. doi: 10.1177/1535370220968752. Epub 2020 Nov 12.

MeSH Terms

Conditions

Osteoporosis

Condition Hierarchy (Ancestors)

Bone Diseases, MetabolicBone DiseasesMusculoskeletal DiseasesMetabolic DiseasesNutritional and Metabolic Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: The clinical study is a randomized, double-blinded, controlled study aimed to assess the effect of zeolite-intervention in osteoporotic patients on the bone mineral density and bone turnover in comparison to osteoporotic patients control group that received the placebo over a period of for 12 months. The study population will consist of 100 patients with osteoporosis defined according BMD criteria: T score -2, 5 on the femoral neck, and, or T -2, 5 on L1-L5, who have not been treated before, or in whom privies treatment did not been successful, despite a gender or age. The Panaceo and Placebo groups will be divided into 50 and 50 patients.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof.dr.sc. Dalibor Krpan, prim.dr.med.

Study Record Dates

First Submitted

March 8, 2019

First Posted

April 3, 2019

Study Start

January 14, 2015

Primary Completion

March 20, 2017

Study Completion

March 20, 2017

Last Updated

April 3, 2019

Record last verified: 2019-04